A Study of EP0031 in Patients With Advanced RET-altered Malignancies

ClinicalTrials.gov ID: NCT05443126

Public ClinicalTrials.gov record NCT05443126. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 7, 2026, 12:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies

Study identification

NCT ID: NCT05443126
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Ellipses Pharma; Industry
Enrollment: 265 participants

Conditions and interventions

Conditions

Interventions

EP0031 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 29, 2022
Primary completion: Nov 30, 2026
Completion: May 31, 2027
Last update posted: Feb 2, 2026

2022 – 2027

United States locations

U.S. sites: 18
U.S. states: 14
U.S. cities: 16

Facility	City	State	ZIP	Site status
David Geffen School of Medicine at UCLA	Los Angeles	California	90095	Recruiting
Stanford University	Stanford	California	94305	Recruiting
Georgetown University	Washington D.C.	District of Columbia	20057	Recruiting
Florida Cancer Specialist	Fort Myers	Florida	33908	Recruiting
RUSH University Medical Center	Chicago	Illinois	60612	Terminated
Northwestern University	Evanston	Illinois	60208	Recruiting
University of Kentucky	Lexington	Kentucky	40506	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Karmanos	Detroit	Michigan	48201	Terminated
Memorial Sloan Kettering Cancer Center	New York	New York	07920	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
Providence Portland Medical Centre	Portland	Oregon	97213	Recruiting
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	Recruiting
Sarah Cannon	Nashville	Tennessee	37203	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting
Washington University	Seattle	Washington	63130	Recruiting
Seattle Cancer Care / Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05443126, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 2, 2026 · Synced May 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05443126 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →